Streetwise Biotech / Pharmaceuticals Articles



Bob Moriarty

Shovelnose Delivers Gold to Westhaven
Source: Bob Moriarty for Streetwise Reports  (5/17/18)
Bob Moriarty of 321 Gold profiles a company that holds a large land position in the "most unexplored gold belt in British Columbia." More >


Cancer in the Crosshairs: IMV Looks to Deliver Immunotherapy a New Way
Source: Streetwise Reports  (5/16/18)
In this interview with The Life Sciences Report, IMV Inc.'s CEO Fred Ors and Pierre Labbè, chief financial officer, describe the innovative immunotherapy platform technology that has attracted partnerships with big pharma, prompted reorganization of the company, and holds long-term promise for cancer patients. More >


Biotech's Launch of Pain Product Shows Encouraging Early Metrics
Source: Streetwise Reports  (5/12/18)
Francois Brisebois, an analyst with Laidlaw & Co., reviewed this firm's progress since commercially debuting its primary asset.
More >


Concurrent Milestones for Biotech Set to Occur 'on the Horizon'
Source: Streetwise Reports  (5/9/18)
Analyst Douglas Loe with Echelon Wealth Partners discussed this immunotherapy developer's recent and upcoming news. More >


Cell Therapy Firm Finalizing $5.1M Strategic Investment and Partnership with Chinese Company
Source: Streetwise Reports  (5/9/18)
The terms of a proposed agreement between this cell therapy company and YOFOTO, a Chinese health and consumer products company, have been revised and will result in a $5.1 million investment. More >


Jason McCarthy

What Stephen Hawking Missed: Small Biotechs Developing Promising Cell Therapies for Devastating Disease
Source: Streetwise Reports  (5/2/18)
In the second of a two-part series exploring the disruptive cell therapy space, Maxim Group analyst Jason McCarthy takes a look at small-cap companies targeting big-ticket indications and their potential to drive blockbuster value for both patients and investors. More >


Jason McCarthy

Risk Versus Reward: The Value of Cell Therapy for Patients and Investors
Source: Streetwise Reports  (4/25/18)
The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late-stage development. In the first of a two-part series examining the disruptive technology, Maxim Group analyst Jason McCarthy exposes the upsides and downsides of the space, and the companies at its forefront. More >


Analyst Sees Tenbagger in Biotech Firm with 'Favorable Updates'
Source: Streetwise Reports   (4/24/18)
Ram Selvaraju, an analyst with H.C. Wainwright & Co., relayed the most recent news concerning this firm's drug candidate. More >


John McCamant

Biotech Round-Up: M&As, Financings and Immuno-Oncology
Source: John McCamant for Streetwise Reports  (4/18/18)
John McCamant, editor of Medical Technology Stock Letter, reviews biotech M&A and financings, and discusses one company that is expanding its immuno-oncology pipeline. More >


Major Cannabis Player Sees Florida Sales Surge Over 250% and Will Acquire 75% Ownership in Massachusetts Deal
Source: Streetwise Reports  (4/17/18)
A medicinal cannabis company has seen its Florida sales increase 253%, and the company just gained 75% control over a Massachusetts-based dispensary operation, expanding its influence in the medicinal marijuana industry. More >


Biotech Gets Cashed Up Ahead of Pivotal Phase 3 Readouts
Source: Streetwise Reports  (4/17/18)
Ram Selvaraju, an analyst with H.C. Wainwright & Co., discussed the capital raise and upcoming clinical trial data.


More >


Biotech with Deep Pipeline, 'Abundant' Upcoming Catalysts Named Top Pick
Source: Streetwise Reports  (4/11/18)
Douglas Loe, an analyst with Echelon Wealth Partners, made the case for why this biopharmaceutical company merits this status.
More >


Biotech Announces Positive Topline Data in Tourette Syndrome
Source: Streetwise Reports  (4/11/18)
Francois Brisebois, a Laidlaw & Co. analyst, reviewed the recently released study results and upcoming catalysts. More >


RNAi Therapeutics Developer Reports Positive Amyloidosis Data
Source: Streetwise Reports  (4/4/18)
Michael King, an analyst with JMP Securities, reported the new results that this biotech presented in March. More >


CMS Unexpectedly Issues Product Billing Code to Biotech
Source: Streetwise Reports  (4/4/18)
Francois Brisebois, an analyst with Laidlaw & Co., shared and weighed in on the latest news regarding this biopharmaceutical firm.
More >


John McCamant

Biotech Delivers 'Excellent' Phase 2 Data
Source: John McCamant for Streetwise Reports  (4/3/18)
John McCamant, editor of Medical Technology Stock Letter, discusses a biotech with data that he views as positive from a Phase 2 LDL cholesterol lowering trial. More >


Medical Device Firm Posts 'Strong Performance' Globally in Q4/17
Source: Streetwise Reports   (3/28/18)
The company performed strongly in the U.S. and the Asia Pacific region. More >


Regrouped Biotech's Stock Price Could See Fifteenfold Increase
Source: Streetwise Reports  (3/28/18)
A recent conference call provided clinical and financial updates. More >


Andrea Bartzen

Convergence Will Drive the Ultimate Disruption of Life Sciences
Source: Andrea Bartzen for Streetwise Reports  (3/28/18)
Andrea Bartzen, a strategic commercial and communication consultant, describes the disruptive technologies positioned to radically alter the business of life sciences as discussed at a recent BIO CEO Summit Investor Night.
More >


Biotech Advances Treatments for Liver Disease, Pain, Mental Illness
Source: Streetwise Reports  (3/22/18)
With a pipeline expected to generate news flow throughout 2018, this company anticipates a productive 2018.
More >


Two Biotechs Earn Analyst's Top Pick Ranking
Source: Streetwise Reports  (3/19/18)
Echelon Wealth Partners analyst Doug Loe sees blue sky potential for one company's newly approved HIV compound, while the vaccine platform of a second company earned it Top Pick status as well.
More >


Price Target on Biotech Is a 700% Potential Increase
Source: Streetwise Reports  (3/19/18)
Ram Selvaraju, an analyst with H.C. Wainwright & Co., explained Phase 2 data recently released by this company, which documented improvements in patients with inflammatory bowel disease. More >


Biotech's Encouraging Phase 2 Gut Microbiome Data 'Bodes Well' for Phase 3
Source: Streetwise Reports  (3/14/18)
H.C. Wainwright & Co. analyst Ram Selvaraju reported the latest study findings involving this biotherapeutic firm's lead asset. More >


Coverage Initiated on Biotech; Analyst Says, 'Time to Buy'
Source: Streetwise Reports  (3/14/18)
Sarah Weber, an analyst with Piper Jaffray & Co., made the case for investing in this biotherapeutic development firm. More >


Coverage Initiated on Biotech with Interference RNA Platform; Target Price Shows 600% Upside
Source: Streetwise Reports  (3/7/18)
John Vandermosten, an analyst with Zacks Small-Cap Research, analyzed this therapeutics development firm as an investment. More >


Showing Results: 1 to 25 of 741 Next

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe